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Many pathologies of the respiratory tract are inadequately treated with existing small molecule-
based therapies. The emergence of RNA interference (RNAi) enables the post-transcriptional 
silencing of key molecular disease factors that cannot readily be targeted with conventional 
small molecule drugs. Pulmonary administration of RNAi effectors, such as small interfering 
RNA (siRNA), enables direct delivery into the lung tissue, hence reducing systemic exposure. 
Unfortunately, the clinical translation of RNAi is severely hampered by inefficient delivery of 
siRNA therapeutics toward the cytoplasm of the target cells. In order to have a better control 
of the siRNA delivery process, both extra- and intracellular, siRNAs are typically formulated in 
nanosized delivery vehicles (nanoparticles, NPs). In the lower airways, which is the targeted 
site of action for multiple pulmonary disorders, these siRNA-loaded NPs will encounter the 
pulmonary surfactant (PS) layer, covering the entire alveolar surface. The interaction between 
the instilled siRNA-loaded NPs and the PS at this nano-bio interface results in the adsorption 
of PS components onto the surface of the NPs. The formation of this so-called biomolecular 
corona conceals the original NP surface and will therefore profoundly determine the biological 
efficacy of the NP. Though this interplay has initially been regarded as a barrier towards 
efficient siRNA delivery to the respiratory target cell, recent reports have illustrated that the 
interaction with PS might also be beneficial for local pulmonary siRNA delivery. 
 





1. The lung is an attractive target organ for nanoparticle-mediated siRNA delivery 
 
According to the latest update by the World Health Organization (WHO), chronic obstructive 
pulmonary disease (COPD), lower respiratory infections and lung cancer are respectively the 
third, fourth and fifth cause of death worldwide [1], illustrating the limited available therapeutic 
possibilities. In addition, numerous other respiratory disorders are characterized by an urgent 
and unmet therapeutic need. Since the pathophysiology of many of these incurable pulmonary 
diseases can be linked to genetic aberrations, they represent potential candidates for 
treatment by genetic interference [2]. Over the last two decades, extensive research in the field 
of RNA interference (RNAi) has created new therapeutic opportunities, as virtually all genes 
are susceptible to targeting by RNAi effectors such as small interfering RNA (siRNA) duplexes. 
Introduction of siRNAs into the cytoplasm of the diseased cells triggers the RNAi machinery, 
resulting in the sequence-specific post-transcriptional silencing of a target gene [3-5]. 
Targeting the respiratory tract for siRNA delivery offers the possibility for local siRNA 
applications via the intranasal, intratracheal or inhalation route. The direct pulmonary delivery 
of siRNA is considered beneficial since (i) the siRNA dose that needs to be administered is 
lower when compared to systemic administration, (ii) the risk of systemic side effects is 
reduced, and (iii) it provides a noninvasive route of administration and the possibility for self-
administration. Most importantly, pulmonary delivery of siRNA mediates direct access to 
respiratory target cells. Depending on the type of airway disease, the target cells vary from 
epithelial cells, alveolar macrophages, interstitial dendritic cells to T lymphocytes. While 
epithelial cells are key players in e.g. cystic fibrosis [6] or different types of lung cancer [7], 
alveolar macrophages, dendritic cells and T lymphocytes are strongly involved in the 
pathogenesis of inflammatory diseases like asthma or COPD [8, 9]. 
To date, the potential of siRNA-based therapeutics has been evaluated in more than 20 clinical 
trials [10-12], of which only two have addressed the clinical potential of siRNA via inhalation. 
ALN-RSV01 (Alnylam® Pharmaceuticals) is a siRNA designed to inhibit the replication of 
respiratory syncytial virus (RSV) by interrupting the synthesis of the viral nucleocapsid [13]. 
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The Phase IIb trial was initiated in 2010, but unfortunately the primary endpoint was not 
achieved and no further developments in the study program are described [14]. Another siRNA 
that was delivered via direct administration to the lung (ExcellairTM-ZaBeCor Pharmaceuticals), 
targeting spleen tyrosine kinase (Syk), is reported to improve the asthmatic symptoms in a 
Phase I trial. However, details on the clinical outcome of the Phase II trial that started in 2009 
are still not available. 
It is important to note that these studies evaluated the clinical potential of naked siRNA. The 
major advantage of this approach is its simplicity, thereby avoiding possible inflammatory 
responses associated with certain delivery vectors. However, it is anticipated that the local 
therapeutic response can be markedly enhanced through the use of nanoparticles (NPs), since 
they display the possibility to target specific pulmonary cell types and afford a better control of 
the drug delivery process, both extra- and intracellular [15, 16]. Novel nanoformulations are 
needed that show high drug loading, protect the siRNA, improve its pulmonary distribution and 
enhance its cellular internalization in specific lung cell types. 
In this review, an overview of the different extra- and intracellular barriers that siRNA delivery 
platforms encounter following pulmonary delivery is provided, with a special emphasis on the 
pulmonary surfactant (PS) layer. Upon deep lung deposition, the PS layer is one of the first 
interfaces that siRNA-loaded NPs encounter, as it covers the alveolar surface of the respiratory 
tract. At the interface between NPs and biological systems (i.e. nano-bio interface), NPs 
progressively and selectively associate with a range of biomolecules, forming a so-called 
biomolecular corona [17]. Also in the respiratory tract, pulmonary administration of NPs 
typically results in the adsorption of PS components onto their surface. The latter interaction 
might alter the PS function and lead to NP-induced toxicities. On the other hand, it can also 
confer a new biological identity to the inhaled NPs, which profoundly determines their biological 
efficacy [18], a feature that might be exploited for the benefit of pulmonary drug delivery using 
nanomedicines.   
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2. The major barriers in nanoparticle-mediated siRNA delivery to the lung 
 
The local delivery of siRNA towards the respiratory tract in vivo in pre-clinical models has been 
mediated by numerous types of nanosized delivery systems, including lipid-, peptide-, or 
polymer-based NPs [19]. Since recent review papers comprehensively describe the plethora 
of available NPs for pulmonary siRNA delivery, it will not be covered here [20, 21]. Instead we 
will focus on the obstacles that these siRNA-loaded NPs encounter in the respiratory tract, as 
the efficacy of the siRNA delivery system greatly depends on the successful delivery to its 
targeted site of action.  
Despite the advantages of the local route of administration, the lung imposes intrinsic anatomic, 
physical, immunological, and metabolic barriers to efficient siRNA delivery (Figure 1) [22].  
The highly branched structure of the lungs presents an early barrier to the deposition of instilled 
NPs into the lower respiratory tract (Figure 1 (1)). Here, the most important factor that 
determines the regional deposition of particles in the lungs, is the aerodynamic diameter (daer) 
of the liquid or dry powder aerosol. Particles with a daer between 1 and 5 µm are predominantly 
deposited in the lower airways, with a maximum alveolar deposition reached around 3 µm. 
Also aerosols characterized by particles with a daer reduced to the nanoscale mainly result in 
alveolar deposition [23]. Of note, besides the daer of the inhaled particles, also the breathing 
pattern of the patients determines the deposition in the respiratory tract. Lowering the 
respiratory rate (e.g. by breath-holding) for instance prevents the direct particle exhalation, 






Figure 1. The predominant extracellular biological barriers encountered upon 
pulmonary application of siRNA-loaded nanoparticles. 
(1) The highly branched airway structure can present an early barrier to inhaled 
nanoparticles (NPs). For local therapeutic effects, NPs must avoid rapid clearance from 
the lung via (2) translocation across the pulmonary epithelium or (3) the mucociliary 
clearance following entrapment in the respiratory mucus. Furthermore, the interaction 
with (4) the respiratory cellular defense mechanism or (5) the pulmonary surfactant layer 
must be considered. 
PCL: periciliary layer 
 
Considering local pulmonary genetic interference, the translocation of siRNA-loaded NPs to 
extra-pulmonary tissues will also compose an important barrier, as it will decrease the siRNA 
dose present in the respiratory tract (Figure 1 (2)). It has already been demonstrated that the 
pulmonary administration of small molecule drugs leads to efficient and rapid drug transport 
across the air-blood barrier, owing to the high vascularization, large surface area and ultra-thin 
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epithelium of the alveoli (i.e. 0.1-0.4 µm) [25, 26]. Interestingly, also the topical application of 
naked siRNA has shown a rapid systemic distribution [27]. In stark contrast, the translocation 
and accumulation in extra-pulmonary organs of NPs is very limited, again illustrating the need 
of a delivery vehicle to achieve local therapeutic effects and avoid systemic exposure. In 
addition, the majority of the NPs that do translocate, is directed towards the regional lymph 
nodes, a process largely governed by dendritic cells, without further distribution throughout the 
body [28-30].  
Still, the most important elimination route in the airways is the mucociliary clearance (Figure 1 
(3)). The respiratory mucus is primarily composed of a three-dimensional network of cross-
linked and entangled mucin fibers, lying on top of a periciliary layer [31]. The latter is also 
grafted with mucins and proteoglycans that are tethered to the cilia and the epithelial surface 
with increasing density from the top of the layer to its bottom [32]. For local NP-mediated drug 
delivery to mucosal surfaces (e.g. gastrointestinal or vaginal surfaces), different types of 
mucoadhesive NPs were developed in an attempt to increase the local bioavailability [33]. 
However, a fundamental limitation of mucoadhesive NPs in the lungs is the physiological 
turnover of respiratory mucus, which is dramatically elevated by the so-called mucociliary 
clearance [34]. This clearance mechanism is based on the propulsive movement of 109 cilia 
per cm2 in the periciliary layer, resulting in a continuous transport of the mucus layer from the 
upper airways to the esophagus [35]. As a result, mucoadhesive systems are especially 
unsuitable for topical delivery to the lung. In order to avoid the rapid mucociliary clearance, 
siRNA-loaded NPs deposited in the upper airways will have to efficiently penetrate the 
respiratory mucus layer [36, 37], which can be impeded by steric hindrance or adhesive 
interactions.  
The alveolar epithelium is not covered by respiratory mucus, but by a thin layer of PS (Figure 
1 (5)), which will be described in more detail in section 3. An important NP clearance 
mechanism in the alveoli is the phagocytosis of the NPs by alveolar macrophages (AM) 
(Figure 1 (4)). AMs comprise more than 90 % of the pulmonary immune cell population. The 
air-side surface of each alveolus in the human respiratory tract is covered by 12 to 14 AMs 
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[38]. The AMs ingest foreign insoluble particles deposited in the lower airways by phagocytosis, 
which plays a prominent role in the first line defense against inhaled pathogens. Next, the 
particles will be either degraded or the particle-carrying macrophages will migrate to the ciliated 
airways, followed by mucociliary transport to the larynx. Importantly, although it was previously 
assumed that NPs are able to bypass the phagocytic uptake by AM [39], recent findings 
illustrated the opposite namely that AM preferably capture particles with a hydrodynamic 
diameter in the nanometer scale [29, 40, 41]. Of note, in the context of pulmonary pathologies 
with an underlying inflammation, the resident AM might also constitute important target cells 
for siRNA delivery. 
Once the siRNA-loaded NPs have successfully conquered the different extracellular barriers, 
they reach the surface of their target cell in the respiratory tract. At this stage, the NPs have to 
bypass several intracellular barriers prior to reaching its site of action, i.e. the cytoplasm of the 
target cell. Considering the non-drug like properties of siRNA, its high negative charge and 
high molecular weight, this can be a dramatic limiting step in the clinical translation of siRNA 
therapeutics. Therefore, as mentioned before, much effort has been undertaken to incorporate 
siRNA in NPs optimized to circumvent (most of) the intracellular barriers. Figure 2 represent 
the major intracellular barriers, such as cell binding [42], cellular internalization [43, 44], and 
cytoplasmic release of intact siRNA [45, 46]. As illustrated in Figure 2, a transport mechanism 
is required to transfer the NPs across the plasma membrane of the target cell. Generally, non-
viral NPs are internalized via endocytosis after immobilization on the cell surface [43]. Briefly, 
the plasma membrane invaginates locally, thereby surrounding and enclosing the NPs. After 
membrane fission, the NPs are located inside the lumen of the newly formed intracellular 
vesicles, generally referred to as endosomes. Upon maturation, these endosomes will 
intracellularly fuse with lysosomes that represent a hostile environment for the siRNA-loaded 
NPs, given the low pH (± 4.5) and the presence of various degradative enzymes. It is 
imperative for siRNA-loaded NPs to escape from these detrimental compartments in order to 






Figure 2. The predominant intracellular barriers encountered once the siRNA-
loaded nanoparticles reach the respiratory target cell. 
(a) Cellular attachment by e.g. specific recognition by membrane proteins. (b) Endocytic 
uptake of the nanoparticles (NPs) across the plasma membrane. The NPs inside the 
endosomes can either (c) be degraded upon fusion of maturated endosomes with 
lysosomes or (d) escape from the endosomes and (e) release the siRNA. (f) The 
cytosolic siRNA can either be enzymatically degraded or incorporated in the RNA induced 
silencing complex (RISC). 





3. Pulmonary surfactant 
 
3.1. Composition and biophysical activity 
 
Pulmonary surfactant (PS) is synthesized and secreted from the respiratory epithelium by 
alveolar type II cells onto the air-liquid interface, where it reduces surface tension. PS is a 
complex mixture of lipids and proteins, of which the lipid fraction accounts for more than 90 wt% 
(Figure 3). The lipid fraction mainly contains phosphatidylcholine (PC) (around 60-70%) and 
phosphatidylglycerol (PG) (approximately 10%) species. Among PC molecular species, 
dipalmitoylphosphatidylcholine (DPPC) represents 41 % of the total surfactant mass. DPPC is 
essential to sustain the extremely low surface tensions observed during expiration as its 
saturated acyl chains can adopt a highly lateral packed state occupying smaller area per 
molecule compared to unsaturated phospholipids [48, 49]. Other minor phospholipids such as 
phosphatidylethanolamine, phosphatidylinositol, sphingomyelin, as well as 
lysophosphatidylcholine comprise the remainder of the phospholipid pool. Additionally, neutral 
lipids are also present in PS membranes and account for approximately 13% by mass, with 
cholesterol being the most abundant (around 8 % by mass). 
On the other hand, approximately 10% of surfactant in mass is constituted by proteins, 
including specific surfactant proteins, which can be classified with respect to their water affinity: 
hydrophilic proteins (SP-A and SP-D) and hydrophobic proteins (SP-B and SP-C). SP-A, SP-
B and SP-C are membrane-associated proteins and are present in surfactant in small amounts 
(3-5% by mass in the case of SP-A, 0.5-1% by mass for SP-B and SP-C). SP-D is not usually 
associated with surfactant membranes and it constitutes less than 0.5 % by mass [50]. SP-A 
and SP-D belong to the collectin protein family and they are involved in the innate immune 
response and inflammatory responses in the lung as well as in the maintenance of alveolar 





Figure 3. Composition of human pulmonary surfactant. 
Pie chart representing average weight percentage of each component with respect to the 
total mass of pulmonary surfactant. This figure was adapted from Parra et al. [53]. 
(DP)PC: (dipalmitoyl)phosphatidylcholine. PG: phosphatidylglycerol. PL: phospholipids. Chol: 
cholesterol. NL: neutral lipids. SP: surfactant protein. 
 
The major function of PS is to reduce the surface tension at the air-liquid interface of the lower 
airways, thereby preventing collapse of the lung on expiration and stabilizing the respiratory 
surface along compression-expansion breathing cycles [54]. Despite the fact that DPPC and 
PG are the main surface active agents, the presence of the small hydrophobic surfactant 
proteins SP-B and SP-C is strictly required to facilitate phospholipid dynamics during surface 
film formation and stabilization. 
PS is also involved in lung host defense against inflammation and infection [51, 55]. In general 
terms, the hydrophilic section of surfactant proteins is specialized in the clearance of 
pathogens from the alveolar spaces by binding and agglutinating a variety of bacterial, fungal 
or viral pathogens and molecules such as allergens or environmental inorganic particles as 
well as in the modulation of the inflammatory cellular response in the lung. Thus, these proteins 
are in charge of recognition and opsonization of pathogens, presenting them to immune cells 
such as alveolar macrophages and monocytes [56]. However, also in the absence of immune 
cells, they still exhibit intrinsic antimicrobial activity by increasing the permeability of the 
microbial cell membrane [57]. 
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Of note, several pathologic processes may modify the composition, structure and/or function 
of PS. For example, inflammatory pulmonary disorders are often associated with vascular 
injuries, causing an influx of e.g. serum proteins, cholesterol, and free fatty acids into the 
airways. At the air-liquid interface, these molecules will partly inhibit the function of the PS 
layer, resulting in higher surface tensions [58]. In addition, modifications in the composition of 
PS have been reported in several pulmonary disorders. For example, different studies have 
indicated that altered levels of cytokines in the alveolar space can affect the surfactant 
biosynthesis, thereby causing aberrant PS lipid and/or surfactant protein levels [59]. 
 
3.2. Therapeutic use of pulmonary surfactant 
 
The integrated regulation of surfactant synthesis, secretion and metabolism is vital for air 
breathing and ultimately, survival. Indeed, deficiency or inactivation of surfactant affects lung 
compliance and gas exchange and contributes to the development and outcome of severe 
respiratory pathologies, such as neonatal respiratory distress syndrome (NRDS). Preterm 
babies with still immature lungs lack fully differentiated alveolar type II cells, therefore resulting 
in insufficient PS production, which contributes to the pathogenesis of NRDS [60]. Current 
medical practice guidelines recommend respiratory support (mechanical ventilation and nasal 
continuous positive airway pressure) combined with surfactant treatment [61, 62], which 
substantially ameliorates the signs of NRDS and reduces mortality and respiratory morbidity 
in premature babies [63].  
Initial surfactant preparations consisted of synthetic surfactants that contained only 
phospholipids, and lacked surfactant proteins [64]. However, once the presence of the 
hydrophobic surfactant proteins was proven to be essential for the optimal surface activity, 
surfactant preparations extracted from lungs of mammals were developed [65]. These natural 
surfactants, derived from either bovine or porcine animal sources, are extracted from lung 
lavages or minced lungs. Although these natural surfactants have been clinically approved for 
the treatment of NRDS, they also present some drawbacks, such as batch-to-batch variations, 
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high costs per dose, and the potential risk of transmission of pathogens [66]. To avoid these 
possible side effects, several synthetic lung surfactant preparations, consisting of surfactant 
lipids and synthetic surfactant protein analogs, are currently tested in (pre)-clinical trials 
(Venticute®, CHF5633®). The synthetic surfactant Surfaxin® has even recently been approved 
by the Food and Drug Administration for the treatment of NRDS.  
To date, the instillation of exogenous PS is solely used in the treatment of NRDS [63]. However, 
lack or deficiencies of the surfactant system are also associated with other respiratory 
pathologies [60], e.g. acute respiratory distress syndrome (ADRS) or Meconium Aspiration 
Syndrome (MAS). ARDS is characterized by respiratory failure with many different origins, 
manifested in severe pulmonary inflammation, diffuse alveolar damage and alveolar capillary 
leakage [67]. Impaired vascular permeability and pulmonary edema evoke the infiltration of 
surface-active molecules, such as serum and plasma proteins, into the alveolar air-liquid 
interface from the blood capillaries, exerting an inhibitory action on surfactant, generating 
abnormally high surface tensions [68, 69]. MAS results from incorporation of cholesterol into 
surfactant membranes and films when a newborn inhales his first stool before or during delivery 
due to prenatal stress [70]. In this case, PS is inactivated due to the membrane-perturbing 
effect of meconium and particularly by an excess of cholesterol, which alters the structure and 
dynamics of surfactant membranes and films. As the inactivation of PS somehow contributes 
to the development and outcome of these pulmonary disorders, research is currently ongoing 
in order to understand how PS replacement could benefit these lung diseases. 
Importantly, besides the therapeutic use of PS in surfactant replacement therapy, there is an 
increasing interest in the use of PS for the benefit of pulmonary drug delivery. Due to its unique 
biophysical properties mentioned above, PS provides several advantages in drug delivery such 
as (i) the solubilization of poorly-water soluble drugs, (ii) the efficient transport along the entire 
respiratory surface based on its spreading capabilities, and (iii) the protection from other 
extracellular barriers [58]. A recent review has comprehensively described the current 
knowledge on the potential use of PS as a drug delivery vehicle for existing small molecule 
drugs, which will not be covered here [71]. Instead, the major aim in this work is to discuss a 
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number of inspiring reports that evaluated the interaction between NPs and PS components, 
and how this could impact on NP-mediated siRNA delivery to the respiratory tract.  
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4. The interplay between pulmonary surfactant and nanoparticles 
 
4.1. Biomolecular corona formation: evaluating the adhesion of endogenous pulmonary 
surfactant components to engineered nanoparticles 
 
The majority of publications on the adhesion of endogenous PS components onto the NP’s 
surface have focused on the hydrophilic surfactant proteins, SP-A and SP-D. This can be 
attributed to their molecular structure and their function in the innate immune response. As 
outlined above, these proteins function as opsonins to enhance the uptake of inhaled 
particulate matter, such as microorganisms, by antigen presenting cells [72]. It is therefore 
conceivable that these proteins can also adsorb onto the surface of inhaled NPs, thereby 
playing a key role in the formation of a biomolecular corona on inhaled NPs.  
Being members of the collectin family, both hydrophilic surfactant proteins enclose a 
carbohydrate recognition domain (CRD). This domain allows them to associate with 
carbohydrates at the surface of various pathogens, necessary to fulfill their role in the first line 
defense of the respiratory tract. Despite this structural resemblance, SP-A and SP-D showed 
a divergence in their interactions with other biological structures. For example, SP-A has a 
general preference for lipophilic patterns and a high affinity for phospholipids, which allows the 
protein to associate with PS membranes [73]. In contrast, SP-D preferably interacts with strong 
hydrophilic structures, owing to the presence of a large positively charged area near its CRD 
site. For a more detailed insight into the structural determinants of this biomolecular recognition, 
the reader is referred to recent comprehensive reviews available in the literature [72, 74]. 
Recent reports have illustrated that these variations in pattern recognition also exists for the 
interaction of SP-A and SP-D with deposited NPs. While isolated human SP-A preferentially 
interacted with hydrophobic NPs, a pronounced binding of recombinant SP-D to the hydrophilic 
NPs was observed [75]. 
Nevertheless, this work on isolated surfactant proteins did not consider the impact of other 
biomolecules in the lung lining fluid on the propensity for SP-A and SP-D to bind NPs. In an 
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attempt to better represent the in vivo situation, Marchetti and coworkers recently collected 
lung lining fluid from human lung tissue and isolated the soluble proteins. This fraction, 
including SP-D and other non-surfactant related proteins originating from a broad range of 
sources (e.g. pulmonary cell products, serum, etc.), allowed the authors to evaluate the impact 
of these atypical proteins on the SP-D surface association. Apparently, these proteins did not 
significantly alter the binding affinity of SP-D, nor its preference for hydrophilic surface 
modifications [76]. 
However, the latter samples were still depleted of surfactant lipids and surfactant proteins other 
than SP-D. Given the illustrated impact of phospholipids on protein adsorption patterns, it is of 
particular interest to evaluate protein surface association in more complex media [77]. To this 
end, the surfactant protein surface association has been evaluated upon incubation of different 
types of the NPs with bronchoalveolar lavage fluid (BALF) [78-80]. These results indicated that 
the presence of other proteins or phospholipids did not inhibit the association of SP-A and SP-
D on different types of NPs, including carbon nanotubes, metal oxide NPs, or polystyrene NPs. 
Importantly, a recent publication provided the first evidence on the formation of a biomolecular 
corona onto NP’s surface in vivo [81]. In this study, mice were treated with single walled carbon 
nanotubes (SWCNT) via pharyngeal aspiration. Upon different incubation periods, the lungs 
were lavaged and the NPs were recovered from the murine BALF. Next, the adsorbed lipids 
and proteins were identified and quantified via mass spectrometry. Not surprisingly, these data 
revealed that both surfactant lipids and surfactant proteins interact with the SWCNT. The 
predominant components in the biomolecular corona were the phospholipids 
phosphatidylcholine (PC) and phosphatidylglycerol (PG). Computer modeling indicated that an 
uninterrupted coating of phospholipids was formed, where the hydrophobic alkyl chains of the 
phospholipids are oriented toward the hydrophobic NP surface while the hydrophilic 
headgroups are exposed toward the aqueous phase. The surfactant proteins that interacted 
with the SWCNTs were SP-A, SP-D and SP-B. The absence of SP-C was related to the 
lowered SP-C expression level in the pro-inflammatory environment that was induced by the 
SWCNT exposure and to its physicochemical characteristics, making it more difficult to 
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visualize via gel electrophoresis. The computer modeling indicated that SP-D can interact with 
the hydrophilic headgroups of the phospholipid-coated SWCNT. However, the complete 3D 
structure of SP-A and SP-B are not available, implying that details on the surface binding of 
these proteins could not be obtained via computer modeling assessments. Unfortunately, such 
detailed information on the formation of a biomolecular corona on other types of (drug-loaded) 
NPs in vivo is still lacking.  
Of note, to date no information is available in the literature on the interaction between NPs and 
PS in relevant disease models. As mentioned in section 3.1., it is known that the structure and 
composition of PS can be significantly altered in airway disease. On the other hand, pulmonary 
surfactant dysfunction and the concomitant destabilization of the respiratory surface is usually 
associated with reduced compliance and partial alveolar collapse, compromising proper 
aireation and preventing homogeneous distribution of NPs. It is therefore conceivable that all 
these changes can also modulate how inhaled NPs interact with surfactant and vice versa and 
to what extent NPs effectively reach deep regions of the lung . It will be important in future 
research to consider the impact of these alterations on NP toxicity and drug delivery 
performance. 
 
4.2. The impact of pulmonary surfactant on nanoparticle-mediated drug delivery: exploring the 
potential role in pulmonary siRNA delivery 
 
The interaction with biomolecules can obscure the original NP surface. Consequently, it 
confers a new biological ‘identity’ to the NPs characterized by both an altered size and surface 
charge as well as the surface presentation of adsorbed biomolecules which all are critical 
determinants for the toxicological profile and the biological activity of NPs [18]. 
Most studies have focused on the toxicological consequences, which can be manifested on 
two different levels. For one, as the deposited biomolecules conceal the original NP surface, 
the interaction with the target cells will be significantly altered [18]. Consequently, the 
internalized fraction of siRNA-loaded NPs will be modified, which will have a definite impact on 
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the induced cellular toxicity [82]. Besides the cytotoxic consequences, the adhesion of 
biomolecules to the surface of NPs can have an important impact on the normal biophysical 
function of PS. Depending on the amount of adsorbed biomolecules, the associated depletion 
of surfactant lipids and proteins from the air-liquid interface will affect the molecular 
arrangement of surfactant molecules in the PS film [83]. For example, the adhesion of 
surfactant proteins onto the surface of NPs inevitably results in a perturbation of PS function. 
As outlined above, the hydrophilic surfactant proteins SP-A and SP-D contribute to the first line 
host defense in the respiratory tract. As a result, it is conceivable that the sequestration of 
these proteins augment the susceptibility to microbial infections [72, 84]. On the other hand, 
as the hydrophobic proteins SP-B and SP-C are strictly required for the formation and stability 
of the PS film, the squeeze-out of these proteins will have a direct effect on the biophysical 
function of PS [85]. The clarification of the extent and mechanisms involved in this PS inhibition 
by inhaled NPs may guide future development of safer nanomedicines, and has therefore been 
a major topic of investigation [83, 85, 86].  
Besides its impact on nanotoxicity and PS function, the interaction of PS and NPs might also 
affect the biological activity of the latter. As SP-A and SP-D function as opsonins to enhance 
the uptake of inhaled particles, the association of SP-A and SP-D onto the surface of various 
NPs will probably exert a triggering effect on the uptake of NPs by alveolar macrophages. This 
has been observed by Ruge et al., where the surface association of isolated native human SP-
A onto inorganic NPs significantly enhanced their internalization by cultured murine AM [87]. 
In a follow-up publication, these findings were extrapolated to the interaction with isolated 
native human SP-D [75]. The enhancement in phagocytosis by AM upon SP-D 
functionalization has also been illustrated by another research group. Here, a significant higher 
internalization of amine-modified polystyrene NPs (A-PS) by primary AM isolated from wild-
type mice was observed compared with the internalization by primary AM isolated from SP-D 
deficient mice. In addition, it was illustrated that upon interaction with isolated SP-D, the high 
uptake of A-PS by AM isolated from SP-D deficient mice could again be recovered [88]. A 
recent publication investigating the impact of SP-A has highlighted a different outcome. Here, 
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the internalization levels of A-PS were comparable in AM isolated from wild-type mice or from 
SP-A deficient mice. Also the application of exogenous SP-A could not alter the uptake. 
Comparing the adhesive interaction of SP-D and SP-A to A-PS revealed for SP-A only a weak 
surface adhesion, which implies that the observed cellular effects could not be directly related 
to protein association [89]. 
Overall, these studies indicate that certain drug-loaded NPs might be cleared from the lung to 
a greater extent upon interaction with the lung-specific collectins. At the same time, these data 
also demonstrate that including decoration with SP-A or SP-D in NP design could improve their 
uptake by AM, suggesting that it might be beneficial for NP-mediated drug delivery in the 
context of inflammatory disorders.  
So far, no data on the impact of isolated hydrophobic surfactant proteins, i.e. SP-B and SP-C, 
on the internalization of NPs is available. These proteins are structurally different from SP-A 
and SP-D and will therefore likely not induce a similar interaction with AM as illustrated above 
for the pulmonary collectins. 
While the impact of isolated surfactant proteins on pulmonary drug delivery efficacy has not 
yet been explored, synthetic or animal-derived surfactant preparations have recently been 
used to modulate the therapeutic efficacy of nucleic acid loaded NPs. In fact, already in the 
late 1990s, PS preparations have been combined with lipid- and polymer-based delivery 
vehicles. The primary goal of these studies was to understand the barrier properties of PS 
towards the respiratory delivery of therapeutic nucleic acids. To this end, different types of NPs 
were mixed with synthetic or animal-derived surfactant preparations [90-93]. Collectively, these 
reports outlined the incompatibility of cationic lipid-based NPs with PS in vitro [90-92]. It has 
been suggested that the observed inhibitory effect results from disintegration of the lipid NPs 
by the negatively charged lipids present in the PS preparations, resulting in premature release 
of its nucleic acid payload prior to reaching the target cell. This hypothesis was supported in 
recent work by De Backer et al.. Here, experimental evidence on a quantitative release of 
siRNA complexed with LipofectamineTM (i.e. a commercially available lipid-based transfection 
reagent) in the presence of animal-derived surfactant preparations was reported [94]. 
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Interestingly, polymer-based NPs appeared to be more resistant to PS preparations compared 
with lipid-based NPs [92, 93]. Therefore, PS was represented as a critical barrier mainly for 
lipid-based NPs. However, as opposed to the surfactant preparations, bronchoalveolar lavage 
fluid (BALF) inhibited both poly- and lipoplex – mediated gene transfer in vitro [95]. This was 
also confirmed in more recent publications, where transfection efficiencies of lipid-based and 
polymer-based delivery vehicles were compared in cultured lung epithelial cells. Surprisingly, 
the DNA [96] or siRNA [97] transfer mediated by the lipid-NP was less compromised in the 
presence of BALF compared to the polymeric NP. 
Recently, the approach to combine polymeric NPs and PS in a single siRNA delivery vehicle 
has been explored. A single delivery vehicle consisting of siRNA loaded NPs and animal-
derived PS preparations, was evaluated by the group of Kissel [98]. It was reported that the 
siRNA transfer activity of biodegradable NPs, fabricated from diamine modified poly (vinyl 
alcohol) grafted with PLGA, was significantly improved upon the use of Alveofact® during the 
preparation procedure. The production protocol involved a single-step solvent displacement 
technique, applying PS as a surface altering component. Here, the improved siRNA transfer 
activity was attributed to a facilitated cellular uptake [98]. 
Recent findings by De Backer et al. advocate that the high transfection levels cannot always 
be correlated with the alterations in cellular uptake. In the latter report, colloidally stable PS-
coated and siRNA-loaded dextran nanogels were constructed. The high siRNA delivery 
efficiency of the nanogels had previously been established in various cell lines in vitro [99-102]. 
Although the decoration with PS substantially inhibited cellular uptake of the nanogels in lung 
epithelial cells and alveolar macrophages, their gene silencing potential in both cell types was 
maintained or even improved (Figure 4). These intriguing data suggest that PS may enhance 
the fraction of internalized siRNA that is ultimately delivered into the cytosol, possibly mediated 
by the altered interactions with biological membranes, i.e. the cell membrane and/or 
endosomal membrane, in the presence of PS. For instance, the presence of PS could influence 
the predominant cellular uptake mechanism and subsequent intracellular processing, both of 
which could impact on the siRNA delivery efficiency [94, 103].  
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Important to note, the decoration of siNGs, with a PS shell could additionally enhance their 
colloidal stability and largely prevented release of its siRNA payload in the presence of 
competing polyanions (e.g. mucins) [103]. Because of its promising features, this NP platform 
was subsequently evaluated in vivo for siRNA delivery to murine resident alveolar 
macrophages (rAM) [104]. Of note, already more than fifteen years ago, a first in vivo 
experiment on the co-delivery of animal-derived PS and DNA-loaded polymeric NPs was 
conducted [105]. Here, no significant improvement in DNA transfer activity was observed in 
the presence of PS. This is in stark contrast to the in vivo performance of the PS-coated siRNA-
loaded nanogels (siNGs). Both the uncoated and PS-coated siNGs achieved high levels of 
siRNA uptake in rAM, yet only the PS-coated formulation could significantly reduce gene 
expression on the protein level. PS-coated nanogels induced a profound downregulation of 
target mRNA levels, reaching 70 % knockdown upon a single local application (with ~1 mg kg-
1 siRNA dose) in notoriously hard-to-transfect primary rAM [104]. 
 
Figure 4. Impact of pulmonary surfactant on the cellular uptake and gene silencing 
potential of siRNA-loaded nanogels (siNGs) 
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(a) Commercially available pulmonary surfactant (PS) preparations (Curosurf®, Infasurf®) significantly 
inhibit the cellular internalization of siNGs in both lung epithelial cells (human H1299) and alveolar 
macrophages (murine MH-S). Scale bars correspond with 20 µm. Reproduced with permission from 
[94]. Copyright 2013. Elsevier. (b) Cellular uptake by H1299 cells of siNGs or siNGs coated with PS 
(coated siNGs) as a function of siRNA concentration. (c) Evaluation of enhanced green fluorescent 
protein (EGFP) silencing by uncoated siNGs or coated siNGs. To evaluate the uptake, the NGs were 
loaded with Cy5-labeled siRNA (siCy5). To assess the gene silencing potential, they were loaded with 
control siRNA (siCTRL) or active siRNA (siEGFP). (n=3). Reproduced with permission from [103]. 
Copyright 2015. Elsevier.  
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5. Conclusion and future outlook 
 
Inhalation therapy of siRNA is a valuable strategy to silence key molecular targets involved in 
respiratory pathologies. However, formulation of siRNA therapeutics in safe and efficient 
nanosized delivery systems (nanoparticles, NPs) is imperative for clinical translation. Upon 
pulmonary administration, siRNA-loaded NPs have to overcome many extra-and intracellular 
barriers. Many groups have investigated the interaction of (drug-loaded) NPs with pulmonary 
surfactant (PS), i.e. a complex mixture of lipids and proteins, and stated deleterious effects on 
both PS and NP function. In contrast, recent reports described that combining PS and NPs 
into a single polymeric delivery systems might improve siRNA delivery, both in vitro and in vivo. 
Therefore, as synthetic nanomedicines often fail to surmount the numerous biological barriers 
en route to their intracellular target, a growing interest exists in the implementation of bio-
inspired materials, such as PS, to advance the field of macromolecular drug delivery. 
In addition, despite the fact that the instillation of exogenous PS is solely used as standard 
therapeutic intervention for NRDS, research is currently ongoing in order to understand how 
PS replacement could benefit a wider range of lung diseases. As revie123.wed above, it was 
already indicated that PS dysfunction contributes to the development and outcome of several 
respiratory diseases. This implies that the combination of a siRNA-loaded NP and exogenous 
PS may provide new and synergistic therapeutic opportunities for the treatment of lung 
diseases with underlying PS dysfunction. 
In summary, future research addressing the promising features of the co-administration of 
siRNA-loaded NPs and PS may strongly contribute to the design of tomorrow’s effective siRNA 
delivery systems for the local treatment of respiratory pathologies.   
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